Two examples below, matched by medicine, dose and package. Each has its own purchase conditions.
Inspect the cash offers ↓REVIEWED SEPTEMBER 30, 2026
HEALTH / AN EVIDENCE BRIEF
Lower drug prices.
For whom?
By how much?
Trump’s drug-pricing record includes cash offers, Medicaid rebates and a Medicare access program. The price a patient pays depends on the medicine, coverage and offer terms.
Compare the published offersThe statement. The price. The conditions that matter.
An administration promotional video, presented as its claim. Loading the player connects to YouTube.
Open the original 29-second video (opens in a new tab)Full September 18 healthcare announcement · 56:02 (opens in a new tab)
Medicare GLP-1 Bridge patient cost, subject to clinical eligibility and authorization.
CMS eligibility rules (opens in a new tab)White House / CEA estimate of Medicaid taxpayer savings over ten years. Not savings already measured.
Estimate and scope (opens in a new tab)01 / COMPARE THE SAME PRESCRIPTION
A dose. A package.
A price with conditions.
Published self-pay offers, reviewed September 30, 2026. Reference prices are list or displayed comparison prices, not verified amounts that patients previously paid. An insurance copay may be lower.
PUBLISHED SELF-PAY OFFER
Wegovy Pen
0.25 mg/0.5 mL · 4 single-dose pens · 28-day fill
- Reference price
- $1,349.02Manufacturer list price / package
- Cash offer
- $199First two qualifying fills for new patients.Then $349 per 28-day fill
Offer conditions
TrumpRx limits the introductory offer to qualifying fills through December 31, 2026. Age 18+, U.S./territory residence and a valid prescription required. Self-pay; no insurance reimbursement or credit toward deductible/out-of-pocket limits under these offer terms.
PUBLISHED SELF-PAY OFFER
Cetrotide
0.25 mg · 1 powder vial + prefilled diluent syringe · 1 kit
- Reference price
- $316.12TrumpRx original-price reference / kit
- Cash offer
- $22.50Published cash offer per kit; not the cost of a complete fertility treatment course.
Offer conditions
Manufacturer program: age 18+, valid prescription dispensed in the U.S., participating pharmacy and payment without insurance reimbursement. Program terms may change or end.
02 / WHO PAYS, AND WHO QUALIFIES?
Three routes.
Different beneficiaries.
A cash purchase, a government rebate and a patient copay describe different transactions. Keep the payer and eligibility in view.
TrumpRx
Patients use participating manufacturers’ self-pay offers. Prices depend on the exact product and eligibility. A posted discount does not establish the saving against a patient’s own insurance price.
Example: Wegovy offer (opens in a new tab)Medicaid / GENEROUS
Manufacturers provide additional rebates through a voluntary CMS model. The comparison concerns Medicaid’s net cost after rebates, not a universal pharmacy-counter price.
Read the CMS model (opens in a new tab)GLP-1 Bridge
CMS’s program offers a $50 monthly patient cost for eligible Medicare beneficiaries. Coverage circumstances, clinical criteria and prior authorization matter; it is not a $50 offer for every senior or every GLP-1 prescription.
Read the program overview (opens in a new tab)Check eligibility and authorization (opens in a new tab)03 / KEEP THE POLICY RECORD SEPARATE
Earlier law.
Later implementation.
The first ten Medicare negotiated drug prices were agreed in 2024 for January 2026 applicability, under the 2022 Inflation Reduction Act signed by President Biden. CMS announced those agreements in August 2024.
They belong in the inherited policy context. They are a separate program from TrumpRx cash offers and the Trump administration’s most-favored-nation agreements.
Read CMS’s August 2024 announcement (opens in a new tab)04 / READ THE ORIGINALS
Every figure.
A source to inspect.
Reviewed September 30, 2026. Announced offers, signed participation and projected savings describe different stages. This record does not establish nationwide realized savings or the lowest price for every patient.
The administration’s announcement
What was presented, and where to watch it.
Official sourceWhite House: Drug-pricing agreements and savings claims (opens in a new tab)September 18, 2026 · Administration claims; CEA ten-year estimates
Official sourceWhite House: TrumpRx platform introduction (opens in a new tab)February 5, 2026 · Official 29-second promotional video; page date in U.S. time
Official sourceWhite House: President Trump makes an announcement on healthcare (opens in a new tab)September 18, 2026 · Full event recording · 56:02
Program rules & implementation
Participation, eligibility and the earlier statutory program.
Official sourceCMS: GENEROUS applications and signed agreements (opens in a new tab)September 18, 2026 · All 50 states applied; 40 states and Puerto Rico signed at publication
Official sourceCMS: GENEROUS Medicaid model (opens in a new tab)Accessed September 30, 2026 · Voluntary participation, supplemental rebates and state requirements
Official sourceCMS: Medicare GLP-1 Bridge (opens in a new tab)Updated July 13, 2026 · accessed September 30, 2026 · July 2026–December 2027 demonstration; $50 copay outside Part D payment flow
Official sourceCMS: Bridge eligibility and prior authorization (opens in a new tab)Accessed September 30, 2026 · Eligible plans, weight-management indication, clinical criteria and covered products
Official sourceCMS: First ten negotiated Medicare prices for 2026 (opens in a new tab)August 15, 2024 · 2022 statutory authority; 2024 agreements; January 2026 price applicability
Published offers & package records
The government listings and the unit being compared.
Official sourceTrumpRx: Wegovy Pen offer and restrictions (opens in a new tab)Accessed September 30, 2026 · Reference price, first two qualifying fills and subsequent price
Official sourceTrumpRx: Cetrotide 0.25 mg offer (opens in a new tab)Accessed September 30, 2026 · One offered configuration; original-price reference and cash offer
Official sourceDailyMed / NLM: Cetrotide package labeling (opens in a new tab)Label revised July 2025 · accessed September 30, 2026 · How supplied: one 0.25 mg kit, NDC 44087-1225-1
Manufacturer price & eligibility terms
Supplementary commercial sources establish package prices and restrictions. They do not independently establish overall administration savings.
Manufacturer termsNovoCare: Pharmacy self-pay terms and package quantities (opens in a new tab)Accessed September 30, 2026 · Four 0.25 mg pens per 28-day fill; introductory and standard offers
Manufacturer price referenceNovoCare: Wegovy list-price definition (opens in a new tab)Accessed September 30, 2026 · Understanding list price; $1,349.02 per pen package
Manufacturer termsEMD Serono: Fertility Instant Savings (opens in a new tab)Accessed September 30, 2026 · Cetrotide $22.50; self-pay eligibility and participating pharmacies
The 29-second video is the White House’s promotional introduction published February 5, 2026. It presents the administration’s message. The preview is the original official thumbnail. White House media policy ↗. Inclusion does not imply government endorsement.